idalopirdine Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Idalopirdine (INN) (code names Lu AE58054,) is a potent and selective 5-HT6 receptor antagonist under development by Lundbeck as an augmentation therapy for the treatment of cognitive deficits associated with Alzheimer's disease and schizophrenia. As of October 2013 it is in phase III clinical trials.   Wikipedia

Chemistry

  • SMILES: FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1
  • InChIKey: YBAWYTYNMZWMMJ-UHFFFAOYSA-N
  • Mol. Mass: 398.38
  • ALogP: 4.92
  • ChEMBL Molecule:
    idalopirdine  
More Chemistry

Pharmacology

Alternative names

(2-(6-fluoro-1h-indol-3-yl)-ethyl)-(3-(2,2,3,3-tetrafluoropropoxy)benzyl)amine | [benzyl-7-14c]-idalopirdine | [ethyl-1-14c]-idalopirdine | idalopirdine | luae58054 | lu ae58054 | lu-ae58054

Organizations (2)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Alzheimer Disease (Phase 3)

Cognition (Phase 2)

Healthy Volunteers (Phase 1)

Liver Diseases (Phase 1)

Schizophrenia (Phase 2)

Therapeutic Equivalency (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 16
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue